List view / Grid view
From a microbiological perspective, pharmaceutical products fall into two categories – nonsterile and sterile. For both categories manufacturers must eliminate, or minimise, potential health risks to patients related to microorganisms and the toxins they produce, whilst maintaining product quality. Many contributing factors may affect the quality of a medicine or…
9 August 2016 | By Cherwell Laboratories
Cherwell to offer expert insight in environmental monitoring and process validation to both NHS and industrial pharmaceutical manufacturers...
8 August 2016 | By Wickham Laboratories
Wickham Laboratories Ltd is pleased to announce the publication of a joint study with Bioquell on the efficacy of disinfection by hydrogen peroxide...
Particularly in the pharmaceutical industry, microbiological method development and, specifically, method suitability is often overlooked or left until the end of a project. However, it is important to give both method suitability and development due consideration as it can be a complicated process involving wide specifications, vague parameters and the…
In this issue: Biosimilars, Regulation, Packaging, Microfluidics, Microbiology, PAT, Antibiotic Resistance, and much more...
In this Microbiology In-Depth Focus: Risk-based microbiological testing; Improving microbiological assurance for bioburden testing; Microbiology Roundtable...
31 May 2016 | By Eppendorf
Eppendorf's BioBLU 3f Single-Use Vessels specifically address the demands of high cell density fermentation of bacteria, yeasts and fungi...
In this issue: Regulation, Oncology, Single Use, Robotics, Microbiology, PAT, Mass Spectrometry, Drug Delivery, Nanotechnology, and much more...
4 May 2016 | By Mostafa Eissa, Hikma Pharmaceuticals
The microbial contamination of medicinal products constitutes a continuous threat to the health of consumers, which may negatively impact pharmaceutical companies’ reputability. However, multidose sterile pharmaceutical products are prone to contamination either from the normal flora of the human body or from the surrounding environment, following their misuse by patients.…
22 March 2016 | By Cherwell Laboratories
New 2016 Redipor® price list available on request...
In Issue #1 2016: Regulation, Drug Delivery, Raman, PAT, Formulation, NIR, Microbiology, and much more...
Completing risk assessments is an inherent part of good manufacturing practice (GMP) and risk-based environmental control and monitoring (EM) in sterile product filling within isolators and restricted access barrier systems (RABS). This article considers the challenges the pharmaceutical industry faces in characterising conventional risk assessments like failure modes and effects…
The biopharmaceutical industry, especially manufacturing facilities, needs to implement bacterial identification to avoid the occurrence of a problematic microorganism in the final product that could be harmful for the end user and detrimental to a company’s finances and reputation.
29 January 2016 | By Adewale Joseph Ogunleye, Adekunle Ajasin University, Akungba Akoko, Ondo State, Nigeria
This article explores how scientists are developing a fast, qualitative and specific technique for the detection and classification of microorganisms...
In digital version of Issue #6 2015: Microbiology, Screening, PCR, Continuous Manufacturing, PAT, Regulation, and much more...
